A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

NCT06577376 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past

Interventions

DRUG: DP303c
DRUG: Simmitinib tablets
DRUG: Irinotecan liposomes
DRUG: Paclitaxel or docetaxel or irinotecan

Sponsor

Shanghai Runshi Pharmaceutical Technology Co., Ltd